Fisher Asset Management LLC Has $18.55 Million Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fisher Asset Management LLC increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 6.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 324,005 shares of the biopharmaceutical company’s stock after acquiring an additional 20,721 shares during the quarter. Fisher Asset Management LLC owned about 0.25% of Halozyme Therapeutics worth $18,546,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Verdence Capital Advisors LLC increased its holdings in shares of Halozyme Therapeutics by 1.9% in the third quarter. Verdence Capital Advisors LLC now owns 13,232 shares of the biopharmaceutical company’s stock valued at $757,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC grew its stake in Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 254 shares during the last quarter. Fifth Third Bancorp raised its holdings in Halozyme Therapeutics by 2.4% in the 2nd quarter. Fifth Third Bancorp now owns 11,206 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 261 shares during the period. Private Advisor Group LLC lifted its position in Halozyme Therapeutics by 1.8% during the second quarter. Private Advisor Group LLC now owns 22,753 shares of the biopharmaceutical company’s stock worth $1,191,000 after acquiring an additional 412 shares during the last quarter. Finally, Juncture Wealth Strategies LLC boosted its holdings in shares of Halozyme Therapeutics by 3.6% during the third quarter. Juncture Wealth Strategies LLC now owns 12,058 shares of the biopharmaceutical company’s stock worth $690,000 after acquiring an additional 415 shares during the period. Institutional investors own 97.79% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on HALO. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Friday, October 18th. Morgan Stanley lifted their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $68.00 price target on shares of Halozyme Therapeutics in a research note on Wednesday, November 20th. TD Cowen lifted their price objective on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, Wells Fargo & Company lowered shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the stock from $58.00 to $62.00 in a research report on Monday, October 7th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $61.11.

Halozyme Therapeutics Stock Up 1.4 %

Shares of HALO opened at $48.47 on Thursday. The firm has a 50 day simple moving average of $54.00 and a two-hundred day simple moving average of $53.71. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. Halozyme Therapeutics, Inc. has a one year low of $33.15 and a one year high of $65.53. The company has a market cap of $6.17 billion, a P/E ratio of 15.82, a P/E/G ratio of 0.43 and a beta of 1.29.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the business’s stock in a transaction dated Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the transaction, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. The trade was a 5.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders sold 60,000 shares of company stock valued at $3,425,000. Corporate insiders own 2.70% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.